S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN-LABEL SOLACE-KIDS TRIAL

• M Heeney,
• D Rees,
• M de Montalembert,
• I Odame,
• C Brown,
• Y Wali,
• T Nguyen,
• D Lam,
• N Pfender,
• J Kanter

Affiliations

M Heeney

1 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, UNITED STATES

D Rees

2 Department of Paediatric Haematology, King’s College Hospital, London, UNITED KINGDOM

M de Montalembert

3 Hôpital Universitaire Necker-Enfants Malades, Paris, FRANCE

I Odame

4 The Hospital for Sick Children (SickKids) and the University of Toronto, Toronto, CANADA

C Brown

5 Children’s Healthcare of Atlanta, Atlanta, UNITED STATES

Y Wali

6 Sultan Qaboos University, Muscat, OMAN

T Nguyen

7 Novartis Pharma S.A.S., Rueil-Malmaison, FRANCE

D Lam

8 Novartis Pharmaceuticals Co., East Hanover, UNITED STATES

N Pfender

9 Novartis Pharma AG, Basel, SWITZERLAND

J Kanter

10 Division of Hematology-Oncology, University of Alabama-Birmingham, Birmingham, UNITED STATES